Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor

被引:204
作者
Varela-Rohena, Angel [2 ,3 ]
Molloy, Peter E. [4 ]
Dunn, Steven M. [4 ]
Li, Yi [4 ]
Suhoski, Megan M. [2 ,3 ]
Carroll, Richard G. [2 ,3 ]
Milicic, Anita [5 ]
Mahon, Tara [4 ]
Sutton, Deborah H. [4 ]
Laugel, Bruno [5 ]
Moysey, Ruth [4 ]
Cameron, Brian J. [4 ]
Vuidepot, Annelise [4 ]
Purbhoo, Marco A. [4 ]
Cole, David K. [6 ]
Phillips, Rodney E. [5 ]
June, Carl H. [2 ,3 ]
Jakobsen, Bent K. [1 ]
Sewell, Andrew K. [5 ,6 ]
Riley, James L. [2 ,3 ]
机构
[1] Adaptimmune Ltd, Abingdon OX14 4RX, Oxon, England
[2] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[4] Immunocore Ltd, Abingdon OX14 4RX, Oxon, England
[5] Univ Oxford, Oxford OX1 3SY, England
[6] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales
基金
英国惠康基金; 美国国家卫生研究院;
关键词
D O I
10.1038/nm.1779
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV's considerable capacity to vary its HLA-I-restricted peptide antigens allows it to escape from host cytotoxic T lymphocytes (CTLs). Nevertheless, therapeutics able to target HLA-I-associated antigens, with specificity for the spectrum of preferred CTL escape mutants, could prove effective. Here we use phage display to isolate and enhance a T-cell antigen receptor (TCR) originating from a CTL line derived from an infected person and specific for the immunodominant HLA-A*02-restricted, HIVgag-specific peptide SLYNTVATL (SL9). High-affinity (K-D < 400 pM) TCRs were produced that bound with a half-life in excess of 2.5 h, retained specificity, targeted HIV-infected cells and recognized all common escape variants of this epitope. CD8 T cells transduced with this supraphysiologic TCR produced a greater range of soluble factors and more interleukin-2 than those transduced with natural SL9-specific TCR, and they effectively controlled wild-type and mutant strains of HIV at effector-to-target ratios that could be achieved by T-cell therapy.
引用
收藏
页码:1390 / 1395
页数:6
相关论文
共 31 条
[1]   HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells [J].
Betts, Michael R. ;
Nason, Martha C. ;
West, Sadie M. ;
De Rosa, Stephen C. ;
Migueles, Stephen A. ;
Abraham, Jonathan ;
Lederman, Michael M. ;
Benito, Jose M. ;
Goepfert, Paul A. ;
Connors, Mark ;
Roederer, Mario ;
Koup, Richard A. .
BLOOD, 2006, 107 (12) :4781-4789
[2]   Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection [J].
Brander, C ;
Hartman, KE ;
Trocha, AK ;
Jones, NG ;
Johnson, RP ;
Korber, B ;
Wentworth, P ;
Buchbinder, SP ;
Wolinsky, S ;
Walker, BD ;
Kalams, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) :2559-2566
[3]   The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells [J].
Cohen, GB ;
Gandhi, RT ;
Davis, DM ;
Mandelboim, O ;
Chen, BK ;
Strominger, JL ;
Baltimore, D .
IMMUNITY, 1999, 10 (06) :661-671
[4]   Human TCR-Binding affinity is governed by MHC class restriction [J].
Cole, David K. ;
Pumphrey, Nicholas J. ;
Boulter, Jonathan M. ;
Sami, Malkit ;
Bell, John I. ;
Gostick, Emma ;
Price, David A. ;
Gao, George F. ;
Sewell, Andrew K. ;
Jakobsent, Bent K. .
JOURNAL OF IMMUNOLOGY, 2007, 178 (09) :5727-5734
[5]   Compensatory mutation partially restores fitness and delays reversion of escpe mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection [J].
Crawford, Hayley ;
Prado, Julia G. ;
Leslie, Alasdair ;
Hue, Stephane ;
Honeyborne, Isobella ;
Reddy, Sharon ;
van der Stok, Mary ;
Mncube, Zenele ;
Brander, Christian ;
Rousseau, Christine ;
Mullins, James I. ;
Kaslow, Richard ;
Goepfert, Paul ;
Allen, Susan ;
Hunter, Eric ;
Mulenga, Joseph ;
Kiepiela, Photini ;
Walker, Bruce D. ;
Goulder, Philip J. R. .
JOURNAL OF VIROLOGY, 2007, 81 (15) :8346-8351
[6]  
Darden JM, 2000, CYTOMETRY, V40, P141, DOI 10.1002/(SICI)1097-0320(20000601)40:2<141::AID-CYTO8>3.3.CO
[7]  
2-6
[8]   Intrapatient escape in the A*0201-restricted epitope SLYNTVATL drives evolution of human immunodeticiency virus type 1 at the population level [J].
Edwards, CTT ;
Pfafferott, KJ ;
Goulder, PJR ;
Phillips, RE ;
Holmes, EC .
JOURNAL OF VIROLOGY, 2005, 79 (14) :9363-9366
[9]   Reversion of CTL escape-variant immunodeficiency viruses in vivo [J].
Friedrich, TC ;
Dodds, EJ ;
Yant, LJ ;
Vojnov, L ;
Rudersdorf, R ;
Cullen, C ;
Evans, DT ;
Desrosiers, RC ;
Mothé, BR ;
Sidney, J ;
Sette, A ;
Kunstman, K ;
Wolinsky, S ;
Piatak, M ;
Lifson, J ;
Hughes, AL ;
Wilson, N ;
O'Connor, DH ;
Watkins, DI .
NATURE MEDICINE, 2004, 10 (03) :275-281
[10]   HIV and SIVCTL escape: Implications for vaccine design [J].
Goulder, PJR ;
Watkins, DI .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (08) :630-640